chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Bad leg pain in my knee joint; I'm in so much pain from this vaccine I can hardly think straight; his knee is going to hurt/is right knee has been on fire, and it hurts bad; This is a spontaneous report from a contactable consumer (patient). A male patient of an unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot number and expiry dates were not reported), via an unspecified route of administration, on 19Apr2021, as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. Historical vaccine included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot number and expiry date was not reported), on unspecified date, as a single dose for COVID-19 Immunization. Patient stated that he had a bad leg pain in his knee joint from the COVID vaccination and "It's in his leg in knee joint and it was very painful. It's not the good time, he was in so much pain from this vaccine, he could hardly think straight. Patient also stated that he got his second shot last month on 19Apr2021, and for about the last 3 weeks, his right knee has been on fire, and it hurts bad and it was more painful, than burning. Stated that he needs to find out if the pain will go away or he needs to get his leg amputated, his knee really hurts. Stated that one of the vaccine side effects is joint pain and his knee was going to hurt: all events were occurred on an unknown date in Apr2021. He was in frustration and stated he is not getting his question answered. The outcome of the events was unknown.  Information about batch no/lot no has been requested.
Red, tender, warm annular rash at site of injection. Began 1 day after injection was received. This was the #4 injection in the series. Treatment was supportive.
This spontaneous report was received from the office manager and refers to multiple unknown number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medication were not reported. On an unknown date, the patients were vaccinated with improperly stored doses of PNEUMOVAX23 lot # L019836, expiration date 24-MAR-2017; and lot # M004318, expiration date 12-OCT-2017 (dose and route of administration were not reported) for prophylaxis, which were exposed to temperature excursion, a total time in the range of 47°Fahrenheit (F) to 77°F (48F), for a time frame of 8 hours. There was a previous temperature excursion, the total time in the range 47°F to 77°F (55F) for 8 hours. There was no data logger. No adverse effects reported. No product quality complaint was involved. This is one of the several reports from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1703USA013739: US-009507513-1703USA013155: US-009507513-1703USA013741: US-009507513-1703USA013742:
This case was reported by a physician via call center representative and described the occurrence of weakness in a 65-year-old female patient who received SHINGRIX for prophylaxis. On 3rd January 2019, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a week after receiving SHINGRIX, the patient experienced weakness, nausea, vomiting, fever and muscle pain. The patient was treated with TYLENOL. On an unknown date, the outcome of the weakness, nausea, vomiting, fever and muscle pain were unknown. It was unknown if the reporter considered the weakness, nausea, vomiting, fever and muscle pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported but it could be 64 or 65 years. The patient received the 1st dose of SHINGRIX vaccine. The patient experienced weakness, nausea, vomiting, fever and muscle pain. She had been taken TYLNEOL every 4 hours and the fever was still persistent.  She had been bed bound all day. No further details were provided.
p/recv vax, lost conscienceness, fell/hit head on tile floor; suffered severe brain swelling, severe closed head inj, cerebral hematoma w/multiple brain contusions, fx skull, perm optic nerve damage;coma x1mo, hosp x2mo, rehab x 8mo.
Pass away; Got COVID; A spontaneous report was received on from a consumer, concerning an 87-year-old male patient, who received Moderna's COVID-19 (mRNA 1273) vaccine and experienced pass away (death) and COVID (COVID-19).  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 29 Dec 2020, the patient received their first of two planned doses of mRNA-1273 injection for the prophylaxis of COVID-19 infection. Two days after mRNA-1273 injection, the patient's daughter was diagnosed with COVID-19 infection. The daughter states that her mother also got infected with COVID.  On an unknown date, the patient got COVID. It was reported that he passed away. Treatment for the event was not provided.  The cause of death was not provided. The plans for an autopsy were not provided. .; Reporter's Comments: Although the onset date of COVID-19 and the fatal outcome is lacking,  Based on the natural history of COVID-19, the reported event, it is assessed as unlikely related with mRNA-1273.  The actual cause of death cannot be ascertained but assessed as not related and most likely due to the COVID-19 infection.
This spontaneous report was received from a physician refers to a female patient of unknown age. On 01-JUL-2013, the patient was vaccinated with a dose 1 of PROQUAD (lot #, expiry not reported). on 12-JUL-2013, the patient experienced chicken pox after receiving the first shot of the PROQUAD vaccine. Patient sought medical attention: saw the doctor. The outcome of chicken pox was unknown. Additional information has been requested.
Family states patient had been coughing and was weak after the vaccine.  Patient walked to the bathroom and then fell striking her head found in PEA with agonal breathing.  Despite aggressive CPR medications patient remained in asystole. Unknow if Moderna or Phifzer
skin rash post-vaccination; This spontaneous case was reported by a nurse and describes the occurrence of RASH (skin rash post-vaccination) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RASH (skin rash post-vaccination). At the time of the report, RASH (skin rash post-vaccination) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Reporter stated that rash began within 20 hours up to 9 days after vaccine administration.  Treatment provided: Topical steroid cream.   This case was linked to US-MODERNATX, INC.-MOD-2021-027398 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-027398:Group reporting
Post vax, pt developed a low-grade fever, vomiting, and an injection site reaction characterized by redness and pain. The pt was treated with Tylenol and warm baths; he recovered within 36 hours.
Face was cleared of eczema; Unexpected therapeutic effect; Feels very rested; This spontaneous case was reported by a consumer and describes the occurrence of PRE-EXISTING CONDITION IMPROVED (Face was cleared of eczema), THERAPEUTIC RESPONSE UNEXPECTED (Unexpected therapeutic effect) and ENERGY INCREASED (Feels very rested) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Eczema and Food allergy.   On 16-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRE-EXISTING CONDITION IMPROVED (Face was cleared of eczema), THERAPEUTIC RESPONSE UNEXPECTED (Unexpected therapeutic effect) and ENERGY INCREASED (Feels very rested). At the time of the report, PRE-EXISTING CONDITION IMPROVED (Face was cleared of eczema) and THERAPEUTIC RESPONSE UNEXPECTED (Unexpected therapeutic effect) had resolved and ENERGY INCREASED (Feels very rested) outcome was unknown.        Concomitant product use was not provided by the reporter. Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not applicable.
Chills - Low Grade Fever (100) - Redness and Soreness at injection site.
c/o uncontrollable shivers for 1/2hr & cold forehead hot but did not take temp, weak, inc urination, inc thirst;called 911 but did not want to got to hosp;RP was up & had enough 02 in blood;
swelling at the injection site; redness / at the injection site; bruising at the injection site; nausea; body aches; chills; This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a 57-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 20th November 2020, the patient received the 1st dose of Shingrix. On 21st November 2020, 1 days after receiving Shingrix, the patient experienced injection site swelling, injection site erythema, injection site bruising, nausea, general body pain and chills. On an unknown date, the outcome of the injection site swelling, injection site erythema, nausea, general body pain and chills were recovered/resolved and the outcome of the injection site bruising was not recovered/not resolved.   It was unknown if the reporter considered the injection site swelling, injection site erythema, injection site bruising, nausea, general body pain and chills to be related to Shingrix.  Additional details were reported as follows: The patient received Shingrix and experienced redness and swelling at the injection site.  The patient also reports bruising at the injection site, which had not fully resolved.  The patient also experienced chills, body aches, and nausea.   All events except for the bruising at the injection site have resolved. The reporter did not consent to follow up.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 61 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 05Dec2021 (Batch/Lot number: unknown) at the age of 61 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose:1, Manufacture unknown), for Covid-19 Immunization; Covid-19 vaccine (Dose: 2, Manufacture unknown), for Covid-19 Immunization. The following information was reported: OFF LABEL USE (non-serious) with onset 2021, outcome "unknown", described as "Off-label use"; INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 2021, outcome "unknown", described as "Interchange of vaccine products"; IMMUNISATION (non-serious) with onset 05Dec2021, outcome "unknown", described as "received Pfizer booster shot"; VACCINATION SITE PAIN (non-serious), BACK PAIN (non-serious), NECK PAIN (non-serious) all with onset Dec2021, outcome "unknown" and all described as "Injection site pain that started to radiate to back and neck on the left side."; HEADACHE (non-serious) with onset 06Dec2021, outcome "unknown", described as "headache"; PAIN (non-serious) with onset 06Dec2021, outcome "unknown", described as "left side pain"; FATIGUE (non-serious) with onset Dec2021, outcome "unknown", described as "tired".  Additional information: No underlaying condition or other medications. Event took place after use of product.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
The vaccine solution was not diluted prior to administration resulting in a higher than recommended dose being administered. The patient was observed for 15 minutes following administration in which no reaction occurred. The parent was notified of the incident and advised to observe for adverse reactions. Discussed in detail adverse reactions and when to seek medical care.
On hour after receiving the vaccination, pt complained of itching arms, "hot facial cheeks", and slight rash on chest. Pt took 50 mg Diphenhydramine. Refused further medical treatment. Within 15 minutes, symptoms had abated. Paint on arms from remodeling could have played a role.
22 Sep2021 I felt like I had a cold in chest, then I had body aches and headache and loss my sense of smell, on 24 Sep2021, I did a test on 26 Sep2021 and was positive for covid. Shortness of breath and 4Oct2021. 29Sep2021 monoclonal antibodies. I still have shortness of breath, cough and chest pains. 10/11/2021 saw doctor. I have a pressure feeling under eyes, like a heavy feeling.
Report A0369630A describes autism spectrum disorder in a male vaccinee of unspecified age who received hepatitis B vaccine recombinant. This report was received as part of litigation proceedings and has not been verified by a physician or other healthcare professional. Medical history, concurrent conditions were not provided. The vaccinee received vaccine on 26 SEP 1997, 14 NOV 1997, and 16 JUL 1997. The second injection of Engerix B was administered at a shorter than recommended interval from the first injection, and the third injection was administered at a longer than recommended interval from the second injection. The vaccinee's attorney alleged that as a result of the exposure to thimerosal from the above vaccines, vaccinee sustained neurological injuries and a result of those injuries has been diagnosed with autism spectrum disorder. Time to onset from immunization, treatment, and outcome of the autism spectrum disorder were not specified. This report of autism spectrum disorder is considered medically serious.
During physical exertion developed chest pain, shortness of breath, fatigue, diaphoresis and nausea and was transported to a local emergency department where basic cardiac labs were drawn and resulted in elevated troponin levels. Transferred to a higher level of care for a full cardiac workup. Discharged as a cardiac event with frequent follow up and daily cardiac medication. Continue to experience issues since event.
Underside of (L) arm swelled, was fevered, itched, burned & was extremely painful for 7 days. On day 8 when reaction was reported, the arm still itched & burned.
Bones and muscles aching  bad, started early evening.  Horrific headache, early evening, would only get little relief with Tylenol and an ice pack on my head. Woke up this morning 10/7/2023 with a rash on the left side of lower back with itchy rash. My throat is a little sensitive this morning, but the headache along with the aching has subsided.  I just feel  a little off, not totally well. I feel like I should have asked if the vaccine contained ANY sulfa.
Bilateral severely swollen ankles, facial swelling noticed approximately 6-7 hours post vaccine; swelling lasted approximately 3 days.
pt recv vax 10SEP96 & 25DEC96 pt devel a chickenpox rash;pt was seen in MD office & on 30DEC96 w/resolving varicella & a red throat;lab eval on 31DEC96 by a strep screen & f/u cult plate revealed a positive test for strep;
Redness, raised, itchiness, warm to touch started next day. Pt used ice/heat and ibuprofen which helped.
Red Swollen area on Left Deltoid Warm to touch size of a Small orange. Use cool compresses. Take antihistamine etc Benadryl. Ibuprofen or Tylenol as needed.
4days post vax devl running fever; to ER t104 & very lathargic; several tests for various things & couldn't find anything wrong; given antibiotics as precaution; then lost speech & was dx w/autism in DEC90;
achy; tired; sore left arm; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 65-year-old female patient who received Herpes zoster (Shingrix) (batch number GM2Y4, expiry date 10th May 2022) for prophylaxis.   On 8th November 2020, the patient received the 1st dose of Shingrix (intramuscular). On 8th November 2020, less than a day after receiving Shingrix, the patient experienced pain in arm. On 9th November 2020, the patient experienced pain and tiredness. The patient was treated with paracetamol (Tylenol). On an unknown date, the outcome of the pain in arm was not recovered/not resolved and the outcome of the pain and tiredness were recovered/resolved.   It was unknown if the reporter considered the pain in arm, pain and tiredness to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in left arm. The same day, after receiving Shingrix, the patient experienced sore left arm. The patient was also achy and tired. The reporter did not consent to follow up.
got so dizzy that she had to stop; couldn't focus to fold them; could not see how to fold the laundry so she had to stop/blurry vison; This spontaneous case was reported by a patient and describes the occurrence of DIZZINESS (got so dizzy that she had to stop), DISTURBANCE IN ATTENTION (couldn't focus to fold them) and VISION BLURRED (could not see how to fold the laundry so she had to stop/blurry vison) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041C21A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension, High cholesterol, Neuropathy, Arthritis and Indigestion. Concomitant products included HYDROCODONE for Arthritis and Pain, LOVASTATIN for High cholesterol, LOSARTAN for Hypertension, PANTOPRAZOLE for Indigestion, GABAPENTIN for Neuropathy.    On 21-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-May-2021, the patient experienced DIZZINESS (got so dizzy that she had to stop), DISTURBANCE IN ATTENTION (couldn't focus to fold them) and VISION BLURRED (could not see how to fold the laundry so she had to stop/blurry vison). At the time of the report, DIZZINESS (got so dizzy that she had to stop), DISTURBANCE IN ATTENTION (couldn't focus to fold them) and VISION BLURRED (could not see how to fold the laundry so she had to stop/blurry vison) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient stated that she is scheduled to receive the second dose on 18JUN2021 but was really scared because of the side effects she experienced.
PATIENT REPORTED THIS ON 8/25.  PATIENT STATES LEFT ARM IS BRUISED AND HURTING SINCE RECEIVED VACCINE. CANNOT RAISE HER ARM. PATIENT ONLY USED BENGAY AND IT WAS NOT HELPING. The time listed above is an assumption. The information was not documented by the Pharmacist that spoke with the patient regarding this.
Sore Arm; Feeling tired; Headache; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Sore Arm), FATIGUE (Feeling tired) and HEADACHE (Headache) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Aug-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Aug-2021, the patient experienced MYALGIA (Sore Arm), FATIGUE (Feeling tired) and HEADACHE (Headache). At the time of the report, MYALGIA (Sore Arm), FATIGUE (Feeling tired) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Treatment informations were reported. No Concomitant informations were reported.
This spontaneous report was received from a consumer of unknown age refering to herself. The patient's current conditions includes being allergic to feathers and also stated that during the 1970's, she received an unspecified "flu" vaccine and had an unspecified reaction to the vaccine due to the allergy mentioned before. On an unspecified date, reported as few years ago, the patient was vaccinated with ZOSTAVAX for prophylaxis (route, anatomical location, lot number and expiration date were not reported). In 2016, the patient was hospitalized 3 times for pneumonia. At the reporting time, the outcome of pneumonia is unknown. The reporter did not assess the relatedness between ZOSTAVAX and the adverse events. pon internal review, pneumonia was determined to be medically significant.
No known adverse event.  vaccine given to someone who was too young to receive (age 15)
The next day I had severe acute pain in shoulder when making certain movements.  Difficulty raising arm.  Difficulty pickup up items from certain position.
The pt had the vax at approximately 8:30 am. The pt went back to class and apparently left school and went to PMD in the afternoon complaining of teeth hurting, fatigue, dyspnea, flushing, gagging and Mom noticed a blank stare. VS were stable in MD's office.
Within a few hours of administration patient had pain in shoulder.  Pain has persisted and patient reports noticeable swelling still as of 3/26. She states that she can not lift her grandchildren or open cabinets. Patient has been icing and taking OTC pain medications. She complains that she is unable to sleep because of the pain.
A report was received from a health care professional on 11/21/2002 concerning eleven vaccinees between the ages of 56-84 years who were inadvertently administered 1.0ml Fluvirin on an unreported date. On an unreported date, eleven vaccinees were inadvertently administered 1ml Fluvirin. No adverse reaction was reported. There was insufficient information to determine the reporters causality assessment. Update1. 12/31/2002: A follow up report was received from a health care professional indicated that a 64 year old male vaccinee was inadvertently administered 1.0ml Fluvirin on 11/21/2002. Cross Reference with: PJP200200806, PJP200200906, PJP200200905, PJP200200904, PJP200200902, PJP200200901, PJP200200900, PJP200200899, PJP200200898, PJP200200907.